BRIEF-Valeant Pharmaceuticals Q2 GAAP loss per share $0.88

Tue Aug 9, 2016 6:16am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

Aug 9 (Reuters) - Valeant Pharmaceuticals International Inc :

* Valeant Pharmaceuticals reports second quarter 2016 financial results

* Sees FY 2016 revenue $9.9 billion to $10.1 billion

* Q2 earnings per share view $1.48 -- Thomson Reuters I/B/E/S

* Q2 GAAP loss per share $0.88

* "we have taken steps to streamline our portfolio in Q2"

* Entered into a definitive agreement to divest all north american commercialization rights to Ruconest to Pharming Group N.V.

* Sold, or agreed to sell, brodalumab EU rights, synergetics USA OEM business, and Ruconest for a total combined upfront payment of $181 million

* Pharming will also pay valeant certain sales-based milestone payments of up to $65 million   Continued...